^
    Back
    Association details:
    Biomarker:TROP2 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:datopotamab deruxtecan (DS-1062a) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

    Excerpt:
    ...- Archival tumor tissue from initial diagnosis, to the extent that archival tumor tissue is available, for measurement of TROP2 expression levels or other biomarkers....
    Trial ID:
    KEYNOTE-B43
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

    Published date:
    12/03/2021
    Excerpt:
    Dato-DXd also showed potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC PDX models.
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-21-0206